Central and Peripheral Adiposity and Iron Absorption

Not Applicable

Completed

• Conditions: Iron-deficiency; Adiposity

• Registration Number: NCT03642223
• Lead Sponsor: Swiss Federal Institute of Technology

Brief Summary

Adiposity is a state of sub-clinical inflammation, thus hepcidin is increased in adiposity, often leading to iron deficiency in this population group. Central adiposity is generally considered having a greater negative effect on health compared to peripheral adiposity. Whether this can be also seen in hepcidin and thereby in iron absorption is uncertain.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-09-10
• Study First Submitted: 2018-07-24
• Study First Submitted QC: 2018-08-20
• Study First Posted: 2018-08-22
• Primary Completion: 2018-10-18
• Study Completion: 2018-10-18
• Status Verified: 2019-03
• Last Update Submitted: 2019-03-27
• Last Update Posted: 2019-03-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 121

Inclusion Criteria

• either normal-weight (BMI 18-25kg/m2) or overweight/obese (BMI 28-50kg/m2) with either central or peripheral fat deposits based on DEXA

Exclusion Criteria

• Iron Supplement or antibiotic intake within 2 weeks before study start
• diagnosed chronic disease or gastrointestinal disorders
• regular use of medication (except contraceptives)
• pregnancy
• lactation
• smoking
• blood donation or surgery within the last 4 months.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Fractional and total iron absorption	14days after the administration of the test meal

Secondary Outcome Measures

Name	Time	Method
Serum IL-6	at baseline	inflammation status
Serum AGP	at baseline	inflammation status
Serum Hepcidin	at baseline
Serum ferritin	at baseline	iron status
Serum TfR	at baseline	iron status
Serum CRP	at baseline	inflammation status

Trial Locations

Locations (1)

American University of Beirut; 🇱🇧 Beirut, Lebanon